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Background: Aim of our study is to analyze the immunological status in pregnancy for two main TORCH agents,
Toxoplasma and Cytomegalovirus (CMV), and the results of group B streptococcus (GBS) screening, assessing the
risk for congenital infection in a population from Palermo, Italy.
Methods: We retrospectively analyzed the medical records of all inborn live newborns who were born in our
division during 2012, gathering information about the mother, the pregnancy and neonatal hospitalization at birth.
Whenever data were available, we categorized the serologic status of the mothers for Toxoplasma and CMV. We
also considered the results of rectal and vaginal swabs for GBS. We compared the results in Italian and immigrant
mothers. The neonatal outcome was evaluated in all cases at risk.
Results: Prevalence of anti-Toxo IgG antibodies was 17.97%, and was significantly higher in immigrant women
(30% vs 16.4% in Italian women; p = 0.0008). Prevalence of anti-CMV IgG antibodies was 65.87%. Again, it was
significantly higher in immigrant women (91.4% vs 62.5%, p = 3.31e-08). We compared those data with a previous
study performed in our hospital in 2005–2006, and found that the prevalence of anti-Toxoplasma and anti-CMV
antibodies in our population has remained stable, both in the immigrant and in the local population. Seroconversion
rates and neonatal infections were rare: no seroconversions were observed for Toxoplasma, 4 seroconversions for CMV.
One neonatal Toxoplasma infection and two neonatal CMV infections were documented. In some cases with dubious
patterns or probable persistence of IgM, we performed additional tests and follow-up. Vaginal and rectal swabs were
positive for GBS in 7.98% of cases, with no significant difference between the Italian and the immigrant population. No
GBS neonatal sepsis was documented.
Conclusions: The prevalence of Toxoplasma IgG antibodies in pregnant women was low in our population, if
compared with European countries and with other parts of Italy, and is significantly higher in immigrant women. The
prevalence of CMV IgG antibodies was intermediate if compared to other countries, and it was higher in immigrant
women. GBS positivity was low, and comparable in Italian and immigrant mothers. Neonatal infection was rare for all
these agents.
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Neonatal infections, both congenital and nosocomially
acquired, are a major issue of concern and interest for
all neonatal units who therefore develop strategies for
monitoring and prevention of vertical (mother to fetus)
and horizontal (environment to newborn) transmission.
Evaluation of the status of pregnant women for those
infections that can affect the fetus is standard routine.
Toxoplasmosis [1] and CMV [2] infections, in our con-
text, are checked in most pregnancies, as will be ex-
plained in the “Methods” section, and a recto-vaginal
swab for GBS has become an usual practice too, aimed
to prevention of early neonatal sepsis by intrapartum
antibiotic prophylaxis [3].
Many problems, however, still arise in the clinical prac-
tice. The assessment of the immunological status of the
mothers is not always simple, and may require second
level tests such as IgG avidity, Immunoblotting, PCR, es-
pecially when the scenario is not clear at first evaluation
(for example, when both IgG and IgM antibodies are
present at first test, and the timing of infection is not
clear). The same can be said for the evaluation of the neo-
nate who is at risk of congenital infection. Moreover, the
follow-up of the mother during pregnancy is not always
optimal, consistent and complete.
The epidemiology of the immune status for Toxo-
plasma and CMV infections in women of reproductive
age is certainly an important variable in the clinical ap-
proach to these problems. The prevalence of IgG anti-
bodies for those agents in pregnant women varies in
different countries and ethnicities, and according to
socio-economical factors like social class, education, job.
Data available in the scientific literature are limited, and
need to be periodically updated.
For GBS, much has been done to understand its epi-
demiology, its role as an agent of neonatal sepsis and the
best strategies to prevent such an outcome. The Centers
for Disease Control (CDC), an USA federal agency
under the Department of Health and Human Services,
have recommended the practice of universal screening
of pregnant women in the third trimester and intrapar-
tum antibiotic prophylaxis in positive cases. As a conse-
quence of that, neonatal sepsis has been efficiently
controlled in USA, with a reduction in its prevalence
from 1.7/1000 liveborn babies at the beginning of the
’90s to 0.34-0.37/1000 liveborn babies in the last few
years [3].
The aim of our study is to provide some data about
the immunological status in pregnant women for the
two main TORCH agents, Toxoplasma and CMV, and
the results of GBS screening in the third trimester, in
order to assess the risk for congenital infection in the
newborn in a population from the city and province of
Palermo, Sicily (Italy).Methods
We retrospectively analyzed the medical records of all live
babies who were born in the Department of Sciences for
Health Promotion and Mother and Child Care of the Uni-
versity of Palermo from 01/01/2012 to 31/12/2012. For
each of them, we recorded the pertinent information about
the mother, the pregnancy and neonatal hospitalization at
birth, and in particular:
Mother and pregnancy:
 Mother’s age at delivery and mother’s nationality
and country of birth;
 Mother’s antibody status for Toxoplasma and CMV,
as ascertained during pregnancy;
 The results of rectal and vaginal swab test for GBS
in the last trimester of pregnancy;
 Delivery type: vaginal, elective Cesarean Section or
emergency Cesarean Section;
 Maternal Premature Rupture Of Membranes
(PROM) (>18 h before delivery);
Newborn:
 Sex;
 Gestational age;
 Apgar score at 1 and 5 minutes;
 Weight, length and cranial circumference at birth,
and respective percentiles;
 First blood cell count after birth (if available);
 Highest C Reactive Protein (CRP) value (if available)
during hospitalization;
 Neurological, respiratory or alimentary pathologies
during hospitalization;
 Eventual admission to Neonatal Intensive Care Unit
(NICU) for neonatal pathologies;
 Eventual intravenous antibiotic therapy;
Statistical analysis was performed by the open source
statistical software R [4].
Population description
899 live babies were born in our hospital in 2012 (there
were 8 stillborns in the same period, which were not
considered in this study). The total number of deliveries
was 881, with 16 twin births and 1 triplet birth. The
medical records were not available for 8 newborns, so
our analysis was performed on 891 newborns. Tables 1
and 2 sum up the general features of our population.
Screening for toxoplasma, CMV and GBS during preg-
nancy is usually performed routinely, but its execution de-
pends on many variables: the gynecologist who is in care
of the mother during pregnancy (usually a private
gynecologist, or some hospital service), the timing of first
medical control during pregnancy, and the compliance of
Table 1 General features of our population (categorical
data)
Maternal nationality Italian 784 87.89%
Not italian 108 12.11%
Maternal job Housewife 505 66.01%
Employee 170 22.22%
Craftwoman/tradewoman 25 3.27%
Professional 65 8.50%
Delivery type Vaginal 414 46.67%
Elective caesarean section 329 37.09%
Emergency caesarian section 144 16.23%
Sex of the newborn F 455 51.07%
M 436 48.93%
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first evaluation is performed as soon as possible after the
diagnosis of pregnancy, and then repeated, possibly
monthly, in all negative women. Women with the pres-
ence of IgG and absence of IgM antibodies at first evalu-
ation don’t usually undergo any other tests, but there are
some exceptions. If IgG and IgM antibodies are both
present at first test, second level exams are usually per-
formed (IgA, IgG avidity, Immunoblotting) to assess, if
possible, the timing of infection. However, there are many
variations of behavior in individual cases. For our study,
we considered all the cases where at least one routine test
for toxoplasma and/or CMV antibodies had been per-
formed during pregnancy. According to the results of all
tests performed in each individual case, we classified the
mothers in the following categories:
a) Immune mother: Presence of specific IgG antibodies
at first test during pregnancy, absence of IgM
antibodies.
b) Non immune mother: Absence of specific IgG and
IgM antibodies throughout pregnancy.
c) Seroconversion during pregnancy: appearance of
specific IgG and/or IgM antibodies during
pregnancy, after a previous negative test.
d) Presence of IgM antibodies: at least in one test
during pregnancy, with positive IgG antibodies in
the absence of any evidence of seroconversion,
e) Dubious: inconsistent patterns, possible lab errors.Table 2 General features of our population (numerical data)
Mean SD Median Range
Mother’s age (year) 30.46 5.91 30.64 15.57 – 51.49
Gestational age (week) 39 1.8 39.1 26.1 – 42.3
Weight at birth (g) 3174.11 539.14 3220 630 - 4760
Lenght at birth (cm) 49.1 2.6 49.5 31 – 55.4
Cranial circumference (cm) 33.8 1.6 34 23.5 – 39.6We also considered the results of rectal and vaginal
swabs for GBS in the third trimester of pregnancy. This
is usually performed routinely according to the indica-
tions of the CDC [3], but again there are many varia-
tions of practice according to individual gynecologists
and/or mother’s compliance. Moreover, the systematic
practice of this test is relatively recent in our context,
and not yet universally implemented.
A further analysis was performed comparing Italian
mothers and immigrant mothers, to detect possible dif-
ferences between the two groups. Immigrant mothers
were defined as those who were not born in Italy and
were not Italian citizens at birth. In our population, im-
migrant mothers were 10.54%. Most frequent countries
of birth were Romania (20.65%), Bangladesh (16.30%),
Ghana (8.70%) and Sri Lanka (7.61%).
Results
Anti-Toxoplasma antibodies were tested during preg-
nancy, at least once, in 846 cases (94.84%).
IgG antibodies were present in 152/846 pregnant
women, which corresponds to a prevalence of 17.97%
(95% CI = 15.53% - 20.70%). In 3 cases IgM antibodies
were also present at least in one test during pregnancy,
in the absence of any evidence of seroconversion. In
two cases the results of the tests were dubious or in-
consistent. No case with a documented seroconversion
was found.
There was no significant difference in maternal age be-
tween the two groups of immune and non immune
mothers (median 30.9 vs 30.61 years; p = 0.21). Preva-
lence of anti-Toxo antibodies was not significantly re-
lated to maternal job: 17.9% in housewives, 14.2% in
employees, 24% in craftswomen and tradeswomen, 17.5%
in professionals, p = 0.56).
The prevalence of anti-Toxo antibodies was signifi-
cantly higher in immigrant mothers (30% vs 16.4%;
p = 0.0008, chi square test for independence). The ratio
of the prevalence of immune serology in immigrant
mothers vs local mothers was therefore 1.83 (95% CI
1.3 – 2.58).
All 3 newborns from mothers that presented IgM anti-
bodies during pregnancy were referred to the Paediatric
Infectious Diseases Unit for follow-up. One of them was
found to be infected, and was successfully treated for
about one year. In another one, no neonatal infection
was found. The third neonate was lost to follow-up be-
fore his condition could be definitely assessed. In the
two dubious cases, the pattern of maternal tests showed
no real risk for neonatal infection, and was easily ex-
plained as the result of lab errors. Therefore, no neonatal
follow-up was performed.
Anti-CMV antibodies were tested during pregnancy, at
least once, in 797 cases (89.2%).
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women. That corresponds to a prevalence of 65.87% (95%
CI = 62.51% - 69.08%). Only in 4 cases (0.5%) a serocon-
version was observed during pregnancy, while in 8 cases
(1%) IgM antibodies were present together with IgG at
least in one test during pregnancy, in the absence of any
evidence of seroconversion.
In 10 cases (1.25%) the results of the tests were dubi-
ous or inconsistent.
In all cases of seroconversion or presence of IgM anti-
bodies and in most dubious results a test for CMV DNA
in urine was effected in the newborn, in the first week of
life, and it was positive only in two cases, one of the 4
babies from mothers with seroconversion and one of the
8 babies from mothers with IgM antibodies during preg-
nancy. Those two cases of neonatal infection were re-
ferred to the Paediatric Infectious Diseases Unit for
follow-up, and after further clinical evaluation they were
considered completely asymptomatic, and they received
no therapy. Clinical follow-up is ongoing (Table 3).
There was no significant difference in maternal age be-
tween the two groups of CMV immune and non im-
mune mothers (median 30.6 vs 31.18; p = 0.73).
Prevalence of anti-CMV antibodies was weakly related
to maternal job, and we observed a slightly lower preva-
lence in professionals (52.5%, vs 67.9% in housewives,
59.6% in employees, 70.8% in craftswomen and trades-
women, p = 0.049, chi square test for independence).
The prevalence of anti-CMV antibodies was signifi-
cantly higher in immigrant mothers (91.4% vs 62.5%;
(p = 3.31e-08, chi square test for independence). The ra-
tio of the prevalence of immune serology in immigrant
mothers vs local mothers was therefore 1.46 (95% CI
1.34 – 1.59).
Rectal-vaginal swab for GBS was performed in 589
cases (66.03%) and it was positive in 47 cases (7.98%
of the tests, 95% CI = 6.05% - 10.45%). Intrapartum
antibiotic prophylaxis was performed in 28/47 positive
cases (60%), and in 28/542 negative cases (5.2%),
usually for the presence of clinical risk factors. Most
cases where the prophylaxis was not performed were
cesarean sections with intact membranes, but in a few
cases prophylaxis was simply omitted, probably for lack
of the correct information at the time of delivery. How-
ever, no GBS neonatal sepsis was demonstrated in our
population.Table 3 Results of CMV DNA tests in the newborn in
cases at risk for neonatal infection
Type of risk N CMV test in urines CMV +
Maternal seroconversion 4 4 1
Presence of IgM 8 8 1
Dubious serology 10 8 0There was no significant difference in maternal age be-
tween the two groups of positive and negative mothers
(median 29.4% vs 30.9%; p = 0.38).
Prevalence of GBS positivity was not significantly re-
lated to maternal job (p = 0.12).
Unlike what we observed for Toxoplasma and CMV,
the prevalence of positivity for GBS was not significantly
higher in immigrant mothers (7.6% in Italian and 10.6%
in immigrant mothers, p = 0.40).
Discussion
Perinatal infections are a major cause of morbidity and
mortality in the neonatal age in developed countries. Des-
pite the increasing role of horizontally transmitted nosoco-
mial infections [5,6], especially in infants who require
prolonged hospitalization because of underlining risk fac-
tors (prematurity, IUGR, congenital malformations) [7,8],
vertically transmitted perinatal infections are still frequent
and responsible for short and long term sequelae. Neonatal
Units must therefore pay attention both to evaluate and
limit the circulation of outbreaks of nosocomial pathogens
[9] and also to identify the risk of mother to fetus/newborn
transmission of well known dangerous pathogens, such as
Toxoplasma, CMV and Group B Streptococcus.
Our data provide some insights about the immune sta-
tus for Toxoplasma and CMV of pregnant women in
our area (city and province of Palermo, Sicily).
The prevalence of anti-Toxo IgG in our sample is
17.97%, and it is roughly comparable to data from other
Italian regions, confirming the medium-low prevalence
of Toxoplasma infection in Italy if compared with high
prevalence countries (such as France [10] or Austria
[11], Latin America and South-east Asia). Our value
is indeed one of the lowest reported in Italy, very
similar to data from Verona (17.5%), and definitely lower
than values reported from Rome (19.8% - 34.4%) or
Lombardy (22.7%). The only other reported value from
Sicily (Catania) is slightly higher too (23%) [1] (Figure 1).
Our data also show that prevalence of anti-Toxo IgG
antibodies is significantly higher in immigrant women
(30% vs 16.4% in Italian women). Similar differences
have been observed in other countries, for example in
USA, where the general prevalence is 11%, with 7.7% for
US born and 28.1% for foreign born women of child-
bearing age [1].
Obviously, all these differences can be variously ex-
plained taking into account different alimentary habits
and styles, and differences in social and sanitary levels
between local and immigrant populations.
The prevalence of anti-CMV antibodies in our preg-
nant women was medium-high (65.87%), comparable to
other Italian data (Legnano, Lombardy: 68.3%) [12].
According to data from scientific literature, the preva-
lence of CMV infection is higher in developing countries
0% 10% 20% 30% 40% 50% 60%
Italy (Palermo)
Italy (Catania)
Italy (Verona)
Italy (Legnano)
Italy(Rome 2008)
Italy (Rome 2003)
Austria
France
India
Malaysia
Figure 1 Prevalence of Toxoplasma IgGs in women of reproductive age or pregnant in various countries.
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Brazil 98%) [14], while in industrial countries it is defin-
itely lower (Belgium 53.9% [15]; England 54.4% [16],
USA 55.5%) [17] (Figure 2).
In these countries, where the data are available, a sig-
nificant difference in prevalence can be observed be-
tween different types of population: in England, the
prevalence was very high in Asian women (88.2%), and
lowest in the white population (45.9%) [16]; a similar
pattern was observed in the USA (77.2% in black fe-
males, 78.2% in Hispanic females, 45.2% in white females0% 10% 20% 30% 40%
Italy (Legnano)
United States
Belgium
England
Singapore
Iran
Brazil
Turkey
Thailand
Figure 2 Prevalence of CMV IgGs in women of reproductive age or p[17]). In our sample, too, the prevalence is higher in im-
migrant women (91.4% vs 62.5% in Italian women).
Again, differences between social and sanitary levels in
immigrant women, both in their originary countries and
in our country, and in Italian women are the most likely
explanation for the observed data.
We had already performed a similar study in 2005–
2006 in our hospital [18]. Therefore, we were interested
in comparing our new data with those of the previous
study, to verify and confirm those results and/or detect
possible epidemiological variations after a few years. As50% 60% 70% 80% 90% 100%
regnant in various countries.
0%
10%
20%
30%
40%
50%
60%
70%
80%
Toxo IgGs CMV IgGs
2005/2006
2012
Figure 3 Toxoplasma and CMV seroprevalence in 2005/2006 and in 2012.
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and anti-CMV antibodies in our population has remained
quite stable in the last few years, with only a slight reduc-
tion in both cases.
The same is true if we compare data about immigrant
and Italian women from the two studies, as shown in
Figure 4.
Vaginal and rectal swabs in our population of pregnant
women were positive for GBS in 7.98% of cases; this
value is slightly lower than the national average, which is
about 10-20% [19]: in North Eastern Italy it is reported
as 17.9% [20], in Perugia 11.3% [21], in Friuli Venezia
Giulia 19.7% [22].0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2005-2006 2012 2005
Toxoplasma
Figure 4 Toxoplasma and CMV seroprevalence in 2005/2006 and in 2In European countries the prevalence of GBS carriers
among pregnant women varies between 6.5% and 36%
with one third of studies reporting rates of 20% or greater.
Maternal GBS colonization rates in different European
countries appear to be similar to those reported in other
industrialized countries, such as the US (10-30%), Canada
(11–19.5%) and New Zeland (20%) (Figure 5) [23].
We could not find a significant difference between
Italian and immigrant women for GBS prevalence, although
a slightly lower value was observed in local mothers,
which is in line with what is reported in one USA study
(13.7% in white women, vs 21.2% in black and 20.9% in
Hispanic).-2006 2012
CMV
Italian women
Immigrant women
012: differences between Italian women and immigrant women.
0% 5% 10% 15% 20% 25% 30% 35%
Italy (Palermo)
Italy (Perugia)
Italy ( Northen East)
Italy (Friuli)
Greece
France
Germany
Poland
Sub-Saharan Africa
New Zeland
UK
Iran (Tehran)
Czech Republic
Figure 5 GBS: maternal colonization rates in various countries.
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formed in almost all pregnancies (94.84%), while anti-
CMV antibodies were performed in 89.2% of cases; this
is perhaps a sign that gynecologists are, in some meas-
ure, more “aware” of Toxoplasma rather than CMV as a
possible problem in pregnancy. The percentage of tests
is even lower for the GBS swab, which is performed in
only 66% of cases. A possible explanation is that this
practice has only recently found some general imple-
mentation in our local reality.
Seroconversion rates and neonatal infections are rare,
as shown by our data: no seroconversions were observed
for Toxoplasma gondii, 4 seroconversions for CMV. In
some cases with dubious patterns or with probable per-
sistence of IgM, we had to perform additional diagnostic
tests and follow-up.
The incidence of Toxoplasma infection in our sample
was 0.12% (1/846), which is in good accord with the lit-
erature [24].
A test for CMV DNA in the urine of the newborn,
which is a very simple way to immediately diagnose a
congenital infection, was performed in all cases of sero-
conversion and in all dubious cases. We found two neo-
natal infections, both asymptomatic: one in a newborn
whose mother had presented a seroconversion during
pregnancy and another in a newborn whose mother had
IgM and IgG positivity at first test in pregnancy.
According to those numbers, the prevalence of neo-
natal infection would be 0.25% (2/797). However, asymp-
tomatic infections from “immune” mothers cannot be
diagnosed by normal procedures. Since, according to
some studies, these may represent more than half of thetotal infections, the true prevalence of CMV infection in
our population could be about 0.5%, or even higher, in
agreement with values in the literature [25].
Finally, although intrapartum antibiotic prophylaxis
was not consistently performed in all swab positive cases,
no GBS neonatal sepsis could be demonstrated in our
population.
Conclusions
In conclusion, even if congenital infection from Toxo-
plasma and CMV is not a very common event, a reliable
immunological evaluation of the mother during preg-
nancy is certainly the best way to identify cases at risk.
Although our data are the result of a limited analysis,
considering only a relatively small number of pregnan-
cies and newborns, we think that they can be useful to
provide some epidemiological information about our
local situation, and to give an outline of the perinatal
condition of risk for some congenital infections at our
institution. It will certainly be useful to collect further
data in order to confirm the values we reported.
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